Harlequin

Overview

Harlequin is a CBD-dominant cannabis cultivar that became one of the first widely distributed high-CBD strains in the United States after laboratory testing in California began identifying CBD-rich plants around 2009 ^[1][2]. It typically tests with more CBD than THC — frequently in the range of a 5:2 ratio — which makes intoxication mild even at substantial doses Strong evidence.

Its cultural significance is hard to overstate: alongside Cannatonic and ACDC, Harlequin was a proof-of-concept that selectively bred cannabis could express the CBD-dominant chemotype that had largely vanished from the illicit market during decades of THC-focused selection ^[1][3].

Chemistry

Cannabinoids. Harlequin is a CBD-dominant chemotype (often classified as Type II or Type III depending on the phenotype) Strong evidence. Published and lab-reported figures cluster around 8–16% CBD and 4–7% THC, with a CBD:THC ratio commonly cited near 5:2 ^[1][2]. Individual plants vary; the ratio is the more stable trait, not the absolute percentages.

Terpenes. Terpene profiles for Harlequin vary considerably between growers and phenotypes. Commercial lab data has variously reported myrcene, β-caryophyllene, or α-pinene as the dominant terpene Weak / limited. There is no single 'true' Harlequin terpene profile — claims to that effect are marketing Disputed.

A note on folklore. The popular idea that >0.5% myrcene makes a strain 'indica' or 'couch-locky' is not supported by controlled research No data^[4]. Likewise, the indica/sativa label tells you very little about what a chemotype like Harlequin will actually feel like.

Reported effects

Users typically describe Harlequin as clear-headed, mildly relaxing, and only lightly intoxicating — consistent with what would be expected from a low-THC, high-CBD chemotype Anecdote. CBD itself has been shown to attenuate some of the intoxicating and anxiogenic effects of THC in controlled human studies, though the magnitude and conditions of that effect are still debated Disputed^[5][6].

There is no strain-specific clinical evidence for Harlequin. Trials in CBD research use purified or standardized extracts, not flower from a particular cultivar. Any claim that 'Harlequin treats anxiety' or 'Harlequin treats pain' is extrapolation from general CBD/THC research, not evidence about this plant No data.

What you can reasonably expect: a mild, functional experience suitable for daytime use, with less of the racing-heart or paranoia some people get from THC-dominant flower.

Lineage (disputed)

The commonly repeated lineage is: Colombian Gold × Nepali Indica × Thai × Swiss Sativa, attributed to a California grower known as the House of David Collective ^[2][3].

This lineage is undocumented in any verifiable breeder record Disputed. No seed bank or laboratory has published genetic confirmation of these parent strains, and the 'Swiss Sativa' designation in particular is vague. Cannabis lineage claims in general suffer from poor provenance — multiple genetic studies have shown that strain names are unreliable indicators of actual genetic relationships ^[7].

What's well-established: Harlequin was identified and stabilized in Northern California in the late 2000s as part of the early high-CBD cultivar wave. The exact parental cross should be treated as oral history, not fact.

Cultivation basics

Harlequin is generally described by growers as moderately easy, with a sativa-leaning structure — taller plants, longer internodes, and open bud structure Anecdote. Indoor flowering time runs roughly 8–9 weeks. Reported yields are moderate; it is not known as a heavy producer.

Practical considerations:

• Phenotype hunting matters. Because Harlequin has been propagated widely from seed and clone of variable provenance, expressed CBD:THC ratios vary noticeably between sources. If CBD content matters to you (e.g. for a regulated market or personal use), lab-test the specific cut.
• Mold resistance is reported as average; the open structure helps airflow but the long flowering window in humid climates can be a problem.
• Light feeder relative to modern hybrids, per grower reports Anecdote.

Marketing vs. reality

Marketing says: Harlequin is a sativa that gives you focused, clear-headed relief from anxiety, pain, and inflammation thanks to its unique terpene profile.

Reality:

• The 'sativa' label is morphology shorthand, not a predictor of effect Disputed^[4].
• Effects on anxiety, pain, etc. are extrapolated from general CBD research, not Harlequin-specific trials No data.
• There is no single, stable Harlequin terpene profile across growers.
• The lineage story is folklore.

What's actually true and useful: Harlequin is a reliably CBD-dominant flower with a ratio that makes it a reasonable choice if you want the experience of cannabis flower without strong intoxication. That alone is meaningful — it's a category of product the illicit market essentially didn't offer before strains like this re-emerged.

Sources

How this page was made

Related

• ACDC — A CBD-dominant cannabis cultivar derived from Cannatonic, valued for high CBD content and...
• Cannatonic — A high-CBD hybrid from Resin Seeds that helped launch the modern CBD-rich cannabis movemen...